- Report
- June 2024
- 200 Pages
Global
From €7621EUR$7,950USD£6,368GBP
- Report
- October 2024
- 184 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- January 2022
- 200 Pages
Global
From €7190EUR$7,500USD£6,008GBP
- Report
- January 2022
- 60 Pages
Global
From €3787EUR$3,950USD£3,164GBP
- Report
- January 2022
- 60 Pages
Global
From €3787EUR$3,950USD£3,164GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1198EUR$1,250USD£1,001GBP
The Cystinosis Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. Cystinosis is a rare, genetic disorder that affects the kidneys, eyes, muscles, and other organs. Treatment for cystinosis includes cysteamine, a drug that helps reduce the amount of cystine in the body. Cysteamine is available in both oral and intravenous forms. Other drugs used to treat cystinosis include cysteamine eye drops, cysteamine cream, and cysteamine tablets.
The Cystinosis Drug market is a small but growing market, with a number of companies offering treatments for cystinosis. These companies include Raptor Pharmaceuticals, Horizon Therapeutics, and Retrophin. Additionally, several research organizations are actively researching new treatments for cystinosis, including the Cystinosis Research Foundation and the Cystinosis Clinical Research Network. Show Less Read more